Subtype
Pancreatic Exocrine Neoplasm
CI-CAN-00003563Explore in graph →
Non-malignant372 active trials5 approved drugs27 evidence items
- NCIt
- C4445
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00003563Explore in graph →
Clinical trials
977 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04289961 | PDAC Peripheral and Portal Vein Sampling | completed | N/A | 26 | The Christie NHS Foundation TrustOTHER | 1 | Aug 30, 2023 | clinicaltrials |
| NCT00638612 | AdV-tk Therapy With Surgery and Chemoradiation for Pancreas Cancer (PaTK01)(PaTK01) | completed | Phase 1 | 27 | Candel Therapeutics, Inc.INDUSTRY | 1 | Aug 25, 2023 | clinicaltrials |
| NCT03616431 |
| Pancreatic Cancer Dietary Assessment Study(PanDA) |
| completed |
| — |
| 112 |
| The Christie NHS Foundation TrustOTHER |
| 1 |
| Aug 25, 2023 |
| clinicaltrials |
| NCT01726582 | Pancreas Cancer: Molecular Profiling as a Guide to Therapy Before and After Surgery ("Personalized Medicine") | completed | Phase 2 | 229 | Medical College of WisconsinOTHER | 1 | Aug 14, 2023 | clinicaltrials |
| NCT04034238 | Mesothelin-Targeted Immunotoxin LMB-100 in Combination With Tofacitinib in Persons With Previously Treated Pancreatic Adenocarcinoma, Cholangiocarcinoma and Other Mesothelin Expressing Solid Tumors | completed | Phase 1 | 19 | National Cancer Institute (NCI)NIH | 1 | Aug 1, 2023 | clinicaltrials |
| NCT04050085 | SD-101, Nivolumab, and Radiation Therapy in Treating Patients With Chemotherapy-Refractory Metastatic Pancreatic Cancer | completed | Phase 1 | 6 | University of California, DavisOTHER | 1 | Aug 1, 2023 | clinicaltrials |
| NCT02959164 | Decitabine and Gemcitabine for Pancreatic Cancer and Sarcoma | completed | Phase 1 | 36 | Mohammed MilhemOTHER | 1 | Jul 28, 2023 | clinicaltrials |
| NCT02324543 | Study of Gemcitabine/Taxotere/Xeloda (GTX) in Combination With Cisplatin and Irinotecan in Subjects With Metastatic Pancreatic Cancer | completed | Phase 1 / Phase 2 | 47 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Jul 21, 2023 | clinicaltrials |
| NCT05955092 | Exploring the Application of 3D Bioprinting for Personalized Treatment in Pancreatic Ductal Adenocarcinoma | unknown | — | 30 | Peking Union Medical College HospitalOTHER | 1 | Jul 21, 2023 | clinicaltrials |
| NCT01835041 | CPI-613 and Combination Chemotherapy in Treating Patients With Metastatic Pancreatic Cancer | completed | Phase 1 | 21 | Wake Forest University Health SciencesOTHER | 1 | Jul 12, 2023 | clinicaltrials |
| NCT04990037 | A Study of the Safety and Tolerance of CAN04 in Combination With FOLFIRINOX in Subjects With Metastatic Pancreatic Ductal Adenocarcinoma(CAPAFOUR) | completed | Phase 1 | 25 | Cantargia ABINDUSTRY | 2 | Jun 29, 2023 | clinicaltrials |
| NCT02047513 | Neoadjuvant Plus Adjuvant or Only Adjuvant Nab- Paclitaxel Plus Gemcitabine for Resectable Pancreatic Cancer(NEONAX) | completed | Phase 2 | 127 | AIO-Studien-gGmbHOTHER | 1 | Jun 15, 2023 | clinicaltrials |
| NCT02042378 | A Study of Rucaparib in Patients With Pancreatic Cancer and a Known Deleterious BRCA Mutation | completed | Phase 2 | 19 | pharmaand GmbHINDUSTRY | 2 | Jun 13, 2023 | clinicaltrials |
| NCT05895214 | Mesopancreas Study in Pancreatic Cancer(MESOPANC-01) | not yet recruiting | — | 500 | Heinrich-Heine University, DuesseldorfOTHER | 1 | Jun 8, 2023 | clinicaltrials |
| NCT02333188 | Genetic Analysis-Guided Dosing of FOLFIRABRAX in Treating Patients With Advanced Gastrointestinal Cancer | completed | Phase 1 | 50 | University of ChicagoOTHER | 1 | May 31, 2023 | clinicaltrials |
| NCT05754788 | Gene Expression Profile of Resected Pancreatic and Ampullary Adenocarcinoma at Favorable Prognosis | unknown | — | 40 | Fondazione IRCCS Istituto Nazionale dei Tumori, MilanoOTHER | 1 | May 26, 2023 | clinicaltrials |
| NCT05083247 | Preoperative mFOLFIRINOX (or Gem-Nab-P) +/- Isotoxic High-dose SBRT for Borderline Resectable Pancreatic Adenocarcinoma(STEREOPAC) | recruiting | Phase 2 | 256 | Erasme University HospitalOTHER | 1 | May 23, 2023 | clinicaltrials |
| NCT02620865 | BATS With in Combination With Low Dose IL-1 and GM-CSF for Advanced Pancreatic Cancer | completed | Phase 1 / Phase 2 | 2 | Barbara Ann Karmanos Cancer InstituteOTHER | 1 | May 15, 2023 | clinicaltrials |
| NCT03126435 | EndoTAG-1+GEM vs GEM in Patients With Locally Advanced/Metastatic Pancreatic Adenocarcinoma Failed on FOLFIRINOX | completed | Phase 3 | 218 | SynCore Biotechnology Co., Ltd.INDUSTRY | 7 | May 6, 2023 | clinicaltrials |
| NCT02376699 | Safety Study of SEA-CD40 in Cancer Patients | terminated | Phase 1 | 159 | Seagen Inc.INDUSTRY | 1 | May 1, 2023 | clinicaltrials |
| NCT02194829 | Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Gemcitabine Hydrochloride With or Without WEE1 Inhibitor AZD1775 in Treating Patients With Previously Untreated Pancreatic Cancer That Is Metastatic or Cannot Be Removed by Surgery | completed | Phase 1 / Phase 2 | 8 | National Cancer Institute (NCI)NIH | 1 | Apr 25, 2023 | clinicaltrials |
| NCT04164602 | The Occurence of Pancreatic Cancer Studied in Association With Newly Diagnosed Diabetes in the Elderly(NODES) | unknown | — | 2,522 | University of PecsOTHER | 1 | Apr 19, 2023 | clinicaltrials |
| NCT04852367 | PanDox: Targeted Doxorubicin in Pancreatic Tumours(PanDox) | withdrawn | Phase 1 | 0 | University of OxfordOTHER | 1 | Apr 12, 2023 | clinicaltrials |
| NCT02806687 | Effect of Intratumoral Injection of Gene Therapy for Locally Advanced Pancreatic Cancer(THERGAP-02) | completed | Phase 2 | 68 | University Hospital, ToulouseOTHER | 1 | Mar 30, 2023 | clinicaltrials |
| NCT04236102 | KEBI-Cyto Study - Use of the Biocartis Idylla | completed | N/A | 55 | Royal Cornwall Hospitals TrustOTHER | 1 | Mar 29, 2023 | clinicaltrials |
| NCT03717298 | Evaluation of Ocoxin-Viusid® in Advanced Pancreatic Adenocarcinoma | completed | Phase 2 | 30 | Catalysis SLINDUSTRY | 1 | Mar 28, 2023 | clinicaltrials |
| NCT04042480 | A Study of SGN-CD228A in Advanced Solid Tumors | terminated | Phase 1 | 88 | Seagen Inc.INDUSTRY | 5 | Mar 23, 2023 | clinicaltrials |
| NCT03507452 | First-in-human Study of BAY2287411 Injection, a Thorium-227 Labeled Antibody-chelator Conjugate, in Patients With Tumors Known to Express Mesothelin | completed | Phase 1 | 36 | BayerINDUSTRY | 5 | Mar 20, 2023 | clinicaltrials |
| NCT03871959 | Pembrolizumab In Combination With Debio 1143 In Pancreatic and Colorectal Advanced/Metastatic Adenocarcinoma(CATRIPCA) | completed | Phase 1 | 54 | Centre Leon BerardOTHER | 1 | Feb 17, 2023 | clinicaltrials |
| NCT03871790 | Peptide-based Immunization for Colon- and and Pancreas-carcinoma(PICOP-GLOBAL) | completed | — | 50 | CENTOGENE GmbH RostockINDUSTRY | 1 | Feb 10, 2023 | clinicaltrials |
| NCT04605237 | Pancreatic Cancer Recurrence in the Netherlands | unknown | — | 1,750 | UMC UtrechtOTHER | 1 | Feb 2, 2023 | clinicaltrials |
| NCT04077372 | Assessment of a Serious Illness Conversation Guide (SICG) in Advanced Gastro-Intestinal Cancers | terminated | N/A | 12 | Stanford UniversityOTHER | 1 | Jan 27, 2023 | clinicaltrials |
| NCT05433935 | Exploring Biomarkers of the Carcinogenesis of Intraductal Papillary Mucinous Neoplasm (IPMN) of the Pancreas | recruiting | — | 5,000 | Zhejiang UniversityOTHER | 1 | Jan 27, 2023 | clinicaltrials |
| NCT05043532 | Randomized Trial for Optimal Number of Passes Required for Molecular Profiling During EUS-FNB of Pancreatic Cancer | unknown | N/A | 33 | Orlando Health, Inc.OTHER | 1 | Jan 12, 2023 | clinicaltrials |
| NCT03331562 | A SU2C Catalyst® Trial of a PD1 Inhibitor With or Without a Vitamin D Analog for the Maintenance of Pancreatic Cancer | completed | Phase 2 | 24 | Translational Genomics Research InstituteOTHER | 1 | Dec 27, 2022 | clinicaltrials |
| NCT05557851 | Minnelide Along With Abraxane Plus Gemcitabine in Patients With Metastatic Adenocarcinoma of the Pancreas | unknown | Phase 1 | 36 | Minneamrita Therapeutics LLCINDUSTRY | 1 | Dec 9, 2022 | clinicaltrials |
| NCT05380557 | ARTEMIS: Study of Patients With Early Stage Pancreatic Cancer Who Have Undergone Genetic Testing(ARTEMIS) | terminated | — | 2 | Invitae CorporationINDUSTRY | 1 | Dec 7, 2022 | clinicaltrials |
| NCT05356039 | Survival, Quality of Life and Resectability in Locally Advanced Pancreatic Cancer(SQUARE) | recruiting | — | 300 | Umeå UniversityOTHER | 1 | Nov 30, 2022 | clinicaltrials |
| NCT02564146 | First-line Treatment of Metastatic Pancreatic Cancer With Nab-paclitaxel and Gemcitabine(ALPACA) | completed | Phase 2 | 325 | AIO-Studien-gGmbHOTHER | 1 | Nov 22, 2022 | clinicaltrials |
| NCT04400903 | Monitoring Heart Rate Variability for the Early Detection of Pancreatic Cancer | terminated | — | 110 | OHSU Knight Cancer InstituteOTHER | 1 | Nov 22, 2022 | clinicaltrials |
| NCT05593393 | A Long-term Follow-up Cohort Study in Patients With Intraductal Papillary Mucinous Neoplasm | unknown | — | 1,500 | Peking Union Medical College HospitalOTHER | 0 | Nov 14, 2022 | clinicaltrials |
| NCT05611359 | Surgery and Thermal Hepatic Ablation Combined With Chemotherapy in Hepatic Oligometastatic Pancreatic Cancer(HOPE-1) | not yet recruiting | N/A | 60 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 0 | Nov 10, 2022 | clinicaltrials |
| NCT05226572 | Repeated EUS-guided Fine Needle Biopsy of Pancreatic Masses After Non-diagnostic or Inconclusive Results(REuBio) | completed | — | 462 | University of BolognaOTHER | 1 | Nov 8, 2022 | clinicaltrials |
| NCT05604716 | Cross-sectional Follow-up on Digestive and Social Functions of SPN | unknown | — | 300 | Peking Union Medical College HospitalOTHER | 1 | Nov 3, 2022 | clinicaltrials |
| NCT02562716 | S1505: Combination Chemotherapy or Gemcitabine Hydrochloride and Paclitaxel Albumin-Stabilized Nanoparticle Formulation Before Surgery in Treating Patients With Pancreatic Cancer That Can Be Removed by Surgery | completed | Phase 2 | 147 | SWOG Cancer Research NetworkNETWORK | 1 | Oct 19, 2022 | clinicaltrials |
| NCT03665441 | Study of Eryaspase in Combination With Chemotherapy Versus Chemotherapy Alone as 2nd-Line Treatment in PAC(Trybeca-1) | completed | Phase 3 | 512 | ERYtech PharmaINDUSTRY | 3 | Oct 18, 2022 | clinicaltrials |
| NCT05305001 | Germline Mutations Associated With Hereditary Pancreatic Cancer in Unselected Patients With Pancreatic Cancer in Mexico | completed | — | 107 | Instituto Nacional de Ciencias Medicas y Nutricion Salvador ZubiranOTHER | 1 | Oct 18, 2022 | clinicaltrials |
| NCT05571956 | Establishment of Pancreas Cancer and Cancer-associated Fibroblast Using EUS-guided Biopsy Samples | unknown | N/A | 50 | Ajou University School of MedicineOTHER | 1 | Oct 10, 2022 | clinicaltrials |
| NCT03723915 | Pembrolizumab and Pelareorep in Treating Patients With Advanced Pancreatic Cancer | terminated | Phase 2 | 17 | Northwestern UniversityOTHER | 1 | Oct 5, 2022 | clinicaltrials |
| NCT02349867 | Neoadjuvant Chemotherapy Followed by Radiation Therapy and Gemcitabine/Sorafenib/Vorinostat in Pancreatic Cancer | completed | Phase 1 | 23 | Virginia Commonwealth UniversityOTHER | 1 | Sep 19, 2022 | clinicaltrials |
Data updated 23 days agoSource updated Aug 30, 2023source: clinicaltrials